antiinflammatory drug approved in 1993 by the US Food and Drug Administration for once-daily treatment of rheumatoid arthritis and osteoarthritis.
Taken orally, the drug is well absorbed, achieving a peak plasma concentration in 3-6 h. Oxaprozin is extensively metabolized in the liver, undergoing both microsomal oxidation and glucuronic acid conjugation.
Only 1-2% of an oxaprozin dose is excreted as the parent drug (8, 9).
In our investigations, six random urine specimens were obtained from a single patient over a 6-week period and were screened for benzodiazepines with the Emittm d.a.u. able, all 7 were positive for benzodiazepines. GC-MS results were negative for all 10 samples. To determine the effect of the parent drug on the acaEmit and TDx assays, we performed a cross-reactivity study, using oxaprozin extracted from a 600-mg Daypro caplet. 
